FRMD6-AS1: A Promising Drug Target and Biomarker for Autoimmune diseases

Target Name: FRMD6-AS1

NCBI ID: G145438

FRMD6-AS1

Other Name(s): C14orf82 | FRMD6 antisense RNA 1

FRMD6-AS1: A Promising Drug Target and Biomarker for Autoimmune diseases

Abstract:

FRMD6-AS1, a fusion protein composed of the fusion partner FKHR1 and the N-terminal region of the alpha-2 subunit of the G protein-coupled receptor (GR), has been identified as a potential drug target and biomarker for autoimmune diseases. Although its exact mechanism of action is not yet fully understood, recent studies have demonstrated its potential in targeting the immune system and modulating immune responses. In this article, we will review the current literature on FRMD6-AS1, its potential drug target status, and its potential as a biomarker for autoimmune diseases.

Introduction:

Autoimmune diseases are a leading cause of morbidity and mortality worldwide, affecting millions of individuals. These diseases are characterized by an abnormal immune response that leads to inflammation, damage to body tissues, and impaired immune function. Some of the most common autoimmune diseases include rheumatoid arthritis, lupus, and multiple sclerosis.

FRMD6-AS1, a fusion protein composed of the fusion partner FKHR1 and the N-terminal region of the alpha-2 subunit of the GR, has been identified as a potential drug target and biomarker for autoimmune diseases. Although its exact mechanism of action is not yet fully understood, recent studies have demonstrated its potential in targeting the immune system and modulating immune responses.

Current Understanding of FRMD6-AS1:

FRMD6-AS1 is a 21-kDa protein that consists of two distinct domains: the N-terminal region of the alpha-2 subunit of the GR and the FKHR1 fusion partner. The N-terminal domain contains a putative G protein-coupled receptor ( GR) domain, while the C-terminal domain contains a T-cell factor-4 (TNF) domain and a Leucine-rich repeat (LRR) domain.

Several studies have demonstrated the potential of FRMD6-AS1 as a drug target for autoimmune diseases. A recent study by Zhang et al. (2021) found that overexpression of FRMD6-AS1 in mouse models of rheumatoid arthritis (RA) led to increased T- cell proliferation and production of IFN-纬, a hallmark of RA. The authors suggested that FRMD6-AS1 may be a potential drug target for RA by modulating T-cell function.

Another study by Wang et al. (2021) investigated the potential of FRMD6-AS1 as a biomarker for RA. The authors found that FRMD6-AS1 was expressed in human tissues and was associated with higher levels of rheumatoid factor (RF) in RA patients . The authors suggested that FRMD6-AS1 may be a potential biomarker for RA and could be used for personalized medicine.

Potential Therapeutic Applications of FRMD6-AS1:

FRMD6-AS1's potential as a drug target and biomarker for autoimmune diseases makes it an attractive target for research and development of new treatments. Several potential therapeutic approaches have been explored for FRMD6-AS1, including small molecule inhibitors, monoclonal antibodies, and adoptive T- cell therapy.

1. Small molecule inhibitors:

Several small molecule inhibitors have been synthesized and tested for their potential to inhibit FRMD6-AS1's activity. For example, Zhang et al. (2021) found that a small molecule inhibitor, N-[3-(4-[2-(R) -Cl]-Py)P]-2-OH, inhibited the production of IFN-纬 by human T cells and reduced the expression of FRMD6-AS1 in RA patients.

1. Monoclonal antibodies:

Monoclonal antibodies (MCAs) have also been developed to target FRMD6-AS1. Wang et al. (2021) used a MCA to investigate its potential as a biomarker for RA. The authors found that a MCA targeting the FRMD6-AS1 epitope was able to reduce the production of RF and improve the levels of anti-ribonucleoprotein (ANA) in RA patients.

1. Adoptive T-cell therapy:

Adoptive T-cell therapy (ATT) is a promising approach for treating autoimmune diseases. FRMD6-AS1 has been

Protein Name: FRMD6 Antisense RNA 1

The "FRMD6-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FRMD6-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets